A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose.

PubWeight™: 4.02‹?› | Rank: Top 1%

🔗 View Article (PMC 2515139)

Published in Blood on June 05, 2008

Authors

Gregory M Cooper1, Julie A Johnson, Taimour Y Langaee, Hua Feng, Ian B Stanaway, Ute I Schwarz, Marylyn D Ritchie, C Michael Stein, Dan M Roden, Joshua D Smith, David L Veenstra, Allan E Rettie, Mark J Rieder

Author Affiliations

1: Department of Genome Sciences, University of Washington, Seattle, WA98195, USA.

Associated clinical trials:

Genetic Response to Warfarin in Healthy Subjects | NCT01520402

Articles citing this

(truncated to the top 100)

Genotype imputation. Annu Rev Genomics Hum Genet (2009) 18.64

Transcriptomic analysis of autistic brain reveals convergent molecular pathology. Nature (2011) 10.16

A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med (2013) 7.09

A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet (2009) 4.32

Association of CYP2C9*2 with bosentan-induced liver injury. Clin Pharmacol Ther (2013) 3.29

Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet (2013) 3.21

Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood (2010) 2.93

Pharmacogenomics and individualized medicine: translating science into practice. Clin Pharmacol Ther (2012) 2.48

Chapter 11: Genome-wide association studies. PLoS Comput Biol (2012) 2.46

Genome-wide association studies in pharmacogenomics. Nat Rev Genet (2010) 2.14

TAOK3, a novel genome-wide association study locus associated with morphine requirement and postoperative pain in a retrospective pediatric day surgery population. Pain (2014) 2.11

CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant. Mol Pharmacol (2009) 1.92

Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. Pharmacogenomics (2010) 1.82

Personalizing medicine with clinical pharmacogenetics. Genet Med (2011) 1.73

Generating genome-scale candidate gene lists for pharmacogenomics. Clin Pharmacol Ther (2009) 1.66

Warfarin pharmacogenetics. Trends Cardiovasc Med (2014) 1.57

Cancer pharmacogenomics: strategies and challenges. Nat Rev Genet (2012) 1.41

A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. Clin Pharmacol Ther (2010) 1.35

Risk assessment and communication tools for genotype associations with multifactorial phenotypes: the concept of "edge effect" and cultivating an ethical bridge between omics innovations and society. OMICS (2009) 1.35

Biobanks and electronic medical records: enabling cost-effective research. Sci Transl Med (2014) 1.32

Genome-wide association studies in pharmacogenomics: successes and lessons. Pharmacogenet Genomics (2013) 1.30

The future of warfarin pharmacogenetics in under-represented minority groups. Future Cardiol (2012) 1.25

Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis. PLoS One (2012) 1.24

Data-driven methods to discover molecular determinants of serious adverse drug events. Clin Pharmacol Ther (2009) 1.17

Role of pharmacogenomics in the management of traditional and novel oral anticoagulants. Pharmacotherapy (2011) 1.16

Improving the prediction of pharmacogenes using text-derived drug-gene relationships. Pac Symp Biocomput (2010) 1.15

Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9. Pharmacogenet Genomics (2010) 1.14

Genome-wide association study of d-amphetamine response in healthy volunteers identifies putative associations, including cadherin 13 (CDH13). PLoS One (2012) 1.14

Clinically available pharmacogenomics tests. Clin Pharmacol Ther (2009) 1.13

Validation of clinical testing for warfarin sensitivity: comparison of CYP2C9-VKORC1 genotyping assays and warfarin-dosing algorithms. J Mol Diagn (2009) 1.12

Pharmacogenomics: the genetics of variable drug responses. Circulation (2011) 1.10

Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study. Pharmacogenet Genomics (2009) 1.09

Effect of NQO1 and CYP4F2 genotypes on warfarin dose requirements in Hispanic-Americans and African-Americans. Pharmacogenomics (2012) 1.09

Feasibility of implementing a comprehensive warfarin pharmacogenetics service. Pharmacotherapy (2013) 1.09

Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans. Pharmacogenet Genomics (2015) 1.08

Pharmacogenomics in clinical practice and drug development. Nat Biotechnol (2012) 1.08

Pharmacogenomic genome-wide association studies: lessons learned thus far. Pharmacogenomics (2009) 1.08

CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement. Br J Clin Pharmacol (2010) 1.06

Relating human genetic variation to variation in drug responses. Trends Genet (2012) 1.05

Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement. Blood (2011) 1.05

Genome-wide association studies and the genetic dissection of complex traits. Am J Hematol (2009) 1.04

Pharmacogenetics and cardiovascular disease--implications for personalized medicine. Pharmacol Rev (2013) 1.04

Cardiovascular pharmacogenomics. Circ Res (2011) 1.03

The limits of genome-wide methods for pharmacogenomic testing. Pharmacogenet Genomics (2012) 1.02

Association of the GGCX (CAA)16/17 repeat polymorphism with higher warfarin dose requirements in African Americans. Pharmacogenet Genomics (2012) 1.02

Overview of high throughput sequencing technologies to elucidate molecular pathways in cardiovascular diseases. Circ Res (2013) 1.01

The genetics of ischaemic stroke. J Intern Med (2010) 1.01

Association of the 5-aminoimidazole-4-carboxamide ribonucleotide transformylase gene with response to methotrexate in juvenile idiopathic arthritis. Ann Rheum Dis (2011) 1.00

Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis. Clin Pharmacol Ther (2012) 1.00

Scientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice. ISRN Pharmacol (2013) 0.98

Implementation and utilization of genetic testing in personalized medicine. Pharmgenomics Pers Med (2014) 0.97

Functional study of the vitamin K cycle in mammalian cells. Blood (2011) 0.97

Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon. Br J Clin Pharmacol (2014) 0.97

Expectations, validity, and reality in pharmacogenetics. J Clin Epidemiol (2009) 0.96

An integrative method for scoring candidate genes from association studies: application to warfarin dosing. BMC Bioinformatics (2010) 0.96

Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population. J Thromb Haemost (2010) 0.96

Pharmacogenomics of anticoagulants: steps toward personal dosage. Genome Med (2009) 0.95

Understanding the pharmacogenetic approach to warfarin dosing. Heart Fail Rev (2008) 0.94

VKORC1 pharmacogenomics summary. Pharmacogenet Genomics (2010) 0.94

Cytochrome P450-dependent catabolism of vitamin K: ω-hydroxylation catalyzed by human CYP4F2 and CYP4F11. Biochemistry (2013) 0.94

Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment. Ann Rheum Dis (2010) 0.93

Pharmacogenomics: will the promise be fulfilled? Nat Rev Genet (2010) 0.92

Genetic polymorphisms in key methotrexate pathway genes are associated with response to treatment in rheumatoid arthritis patients. Pharmacogenomics J (2012) 0.92

Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements. Eur J Clin Pharmacol (2009) 0.91

Pharmacogene regulatory elements: from discovery to applications. Genome Med (2012) 0.91

Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians. BMC Med Genet (2011) 0.90

Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population. Eur J Clin Pharmacol (2013) 0.90

Assessing cytochrome P450 and UDP-glucuronosyltransferase contributions to warfarin metabolism in humans. Chem Res Toxicol (2009) 0.90

Pharmacogenomics: application to the management of cardiovascular disease. Clin Pharmacol Ther (2011) 0.89

Pharmacogenomics and patient care: one size does not fit all. Sci Transl Med (2012) 0.89

Musings on genome medicine: genome wide association studies. Genome Med (2009) 0.89

Integrating systems biology sources illuminates drug action. Clin Pharmacol Ther (2014) 0.88

Pharmacogenomics discovery and implementation in genome-wide association studies era. Wiley Interdiscip Rev Syst Biol Med (2012) 0.88

A pharmacogenetics-based warfarin maintenance dosing algorithm from Northern Chinese patients. PLoS One (2014) 0.87

Pathway analysis of genome-wide data improves warfarin dose prediction. BMC Genomics (2013) 0.87

Prediction of warfarin dose reductions in Puerto Rican patients, based on combinatorial CYP2C9 and VKORC1 genotypes. Ann Pharmacother (2012) 0.87

Warfarin anticoagulant therapy: a Southern Italy pharmacogenetics-based dosing model. PLoS One (2013) 0.87

Pharmacogenetics of warfarin: challenges and opportunities. J Hum Genet (2013) 0.87

Pharmacogenetics and personal genomes. Per Med (2009) 0.86

Genetics and genomics in nursing: evaluating Essentials implementation. Nurse Educ Today (2010) 0.86

A novel, single algorithm approach to predict acenocoumarol dose based on CYP2C9 and VKORC1 allele variants. PLoS One (2010) 0.85

Fine-mapping nicotine resistance loci in Drosophila using a multiparent advanced generation inter-cross population. Genetics (2014) 0.85

Effect of single-dose rifampin on the pharmacokinetics of warfarin in healthy volunteers. Clin Pharmacol Ther (2010) 0.85

Implementing genotype-guided antithrombotic therapy. Future Cardiol (2010) 0.85

Drug-gene interactions and the search for missing heritability: a cross-sectional pharmacogenomics study of the QT interval. Pharmacogenomics J (2013) 0.84

Controlling Population Structure in Human Genetic Association Studies with Samples of Unrelated Individuals. Stat Interface (2011) 0.84

Hypertension and aging. Ageing Res Rev (2016) 0.84

Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation. Pharmacogenomics (2012) 0.83

VKORC1 -1639G>A and CYP2C9*3 are the major genetic predictors of phenprocoumon dose requirement. Eur J Clin Pharmacol (2010) 0.83

Role of cytochrome P450 genotype in the steps toward personalized drug therapy. Pharmgenomics Pers Med (2011) 0.83

Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group. Circulation (2012) 0.83

Evidence for a pharmacogenetic adapted dose of oral anticoagulant in routine medical practice. Eur J Clin Pharmacol (2008) 0.82

Warfarin pharmacogenomics in children. Pediatr Blood Cancer (2013) 0.82

Personalized cardiovascular medicine: concepts and methodological considerations. Nat Rev Cardiol (2013) 0.82

The influence of pharmacogenetics and cofactors on clinical outcomes in kidney transplantation. Expert Opin Drug Metab Toxicol (2011) 0.82

Warfarin pharmacogenetics: challenges and opportunities for clinical translation. Front Pharmacol (2012) 0.81

Pharmacogenomics of anti-platelet and anti-coagulation therapy. Curr Cardiol Rep (2013) 0.81

Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin. Semin Thromb Hemost (2012) 0.81

A conceptual framework for pharmacodynamic genome-wide association studies in pharmacogenomics. Drug Discov Today (2011) 0.81

Copy number variation and warfarin dosing: evaluation of CYP2C9, VKORC1, CYP4F2, GGCX and CALU. Pharmacogenomics (2011) 0.81

Articles cited by this

Global variation in copy number in the human genome. Nature (2006) 57.50

Mapping and sequencing of structural variation from eight human genomes. Nature (2008) 30.28

Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet (2008) 20.73

Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics (2003) 17.92

Imputation-based analysis of association studies: candidate regions and quantitative traits. PLoS Genet (2007) 15.55

Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am J Hum Genet (2005) 14.09

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med (2005) 8.77

Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med (2008) 7.13

Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation (2007) 5.99

Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature (2004) 5.95

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA (2002) 5.26

A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood (2004) 4.70

Identification of the gene for vitamin K epoxide reductase. Nature (2004) 4.52

CYP4F2 genetic variant alters required warfarin dose. Blood (2008) 4.23

Pattern of sequence variation across 213 environmental response genes. Genome Res (2004) 3.93

The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Ann Intern Med (1996) 3.79

Power to detect risk alleles using genome-wide tag SNP panels. PLoS Genet (2007) 3.29

Association of warfarin dose with genes involved in its action and metabolism. Hum Genet (2006) 3.27

Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther (2006) 3.06

Estimating coverage and power for genetic association studies using near-complete variation data. Nat Genet (2008) 2.80

Evaluation of genetic factors for warfarin dose prediction. Clin Med Res (2007) 2.37

VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation. Clin Pharmacol Ther (2006) 2.19

Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. J Thromb Thrombolysis (2007) 2.12

The patterns of natural variation in human genes. Annu Rev Genomics Hum Genet (2005) 2.12

Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study. J Thromb Thrombolysis (2006) 1.78

The pharmocogenomics of warfarin: closing in on personalized medicine. Mol Interv (2006) 1.61

CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics (2000) 1.43

Gamma-glutamyl carboxylase (GGCX) tagSNPs have limited utility for predicting warfarin maintenance dose. J Thromb Haemost (2007) 1.41

A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin. Epilepsy Res (1999) 1.26

Warfarin dosing and cytochrome P450 2C9 polymorphisms. Thromb Haemost (2004) 1.12

Identifying the genotype behind the phenotype: a role model found in VKORC1 and its association with warfarin dosing. Pharmacogenomics (2007) 1.12

Automated high-throughput sex-typing assay. Biotechniques (2004) 1.06

Articles by these authors

Mapping and sequencing of structural variation from eight human genomes. Nature (2008) 30.28

Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21

Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet (2003) 21.52

Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet (2008) 20.73

Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science (2012) 17.12

Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. Nature (2012) 14.76

Exome sequencing identifies MLL2 mutations as a cause of Kabuki syndrome. Nat Genet (2010) 12.63

Exome sequencing in sporadic autism spectrum disorders identifies severe de novo mutations. Nat Genet (2011) 11.94

Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions. Bioinformatics (2003) 9.91

The eMERGE Network: a consortium of biorepositories linked to electronic medical records data for conducting genomic studies. BMC Med Genomics (2011) 9.20

Analysis of 6,515 exomes reveals the recent origin of most human protein-coding variants. Nature (2012) 8.91

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med (2005) 8.77

Azithromycin and the risk of cardiovascular death. N Engl J Med (2012) 8.18

Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med (2009) 7.89

Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med (2008) 7.13

Population history and natural selection shape patterns of genetic variation in 132 genes. PLoS Biol (2004) 7.11

A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med (2013) 7.09

PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene-disease associations. Bioinformatics (2010) 7.07

Evidence for substantial fine-scale variation in recombination rates across the human genome. Nat Genet (2004) 6.99

Robust replication of genotype-phenotype associations across multiple diseases in an electronic medical record. Am J Hum Genet (2010) 6.44

Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders. Science (2012) 6.21

Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med (2004) 6.21

ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation (2006) 5.95

ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol (2006) 5.81

Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.57

Optimal unified approach for rare-variant association testing with application to small-sample case-control whole-exome sequencing studies. Am J Hum Genet (2012) 5.48

Additional SNPs and linkage-disequilibrium analyses are necessary for whole-genome association studies in humans. Nat Genet (2003) 5.30

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA (2002) 5.26

Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet (2002) 5.17

Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med (2014) 4.94

Implementing genomic medicine in the clinic: the future is here. Genet Med (2013) 4.89

Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. Nat Biotechnol (2013) 4.85

Genomic regions exhibiting positive selection identified from dense genotype data. Genome Res (2005) 4.81

Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med (2003) 4.58

VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 4.50

Global epidemiology of hepatitis B virus. J Clin Gastroenterol (2004) 4.48

New drugs for rheumatoid arthritis. N Engl J Med (2004) 4.38

The Electronic Medical Records and Genomics (eMERGE) Network: past, present, and future. Genet Med (2013) 4.37

CYP4F2 genetic variant alters required warfarin dose. Blood (2008) 4.23

Common missense variant in the glucokinase regulatory protein gene is associated with increased plasma triglyceride and C-reactive protein but lower fasting glucose concentrations. Diabetes (2008) 4.20

Concern Calmodulin kinase II and arrhythmias in a mouse model of cardiac hypertrophy. Circulation (2002) 4.16

A balanced accuracy function for epistasis modeling in imbalanced datasets using multifactor dimensionality reduction. Genet Epidemiol (2007) 4.15

Casq2 deletion causes sarcoplasmic reticulum volume increase, premature Ca2+ release, and catecholaminergic polymorphic ventricular tachycardia. J Clin Invest (2006) 4.06

Common variants in KCNN3 are associated with lone atrial fibrillation. Nat Genet (2010) 3.97

A rare variant in MYH6 is associated with high risk of sick sinus syndrome. Nat Genet (2011) 3.94

Pattern of sequence variation across 213 environmental response genes. Genome Res (2004) 3.93

Haplotype diversity across 100 candidate genes for inflammation, lipid metabolism, and blood pressure regulation in two populations. Am J Hum Genet (2004) 3.91

Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. N Engl J Med (2016) 3.88

Variants near FOXE1 are associated with hypothyroidism and other thyroid conditions: using electronic medical records for genome- and phenome-wide studies. Am J Hum Genet (2011) 3.85

Principles of human subjects protections applied in an opt-out, de-identified biobank. Clin Transl Sci (2010) 3.84

Comprehensive identification and characterization of diallelic insertion-deletion polymorphisms in 330 human candidate genes. Hum Mol Genet (2004) 3.73

Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat Genet (2012) 3.71

Polymorphisms of the HNF1A gene encoding hepatocyte nuclear factor-1 alpha are associated with C-reactive protein. Am J Hum Genet (2008) 3.61

Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc Natl Acad Sci U S A (2011) 3.54

Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med (2009) 3.35

Identification of genomic predictors of atrioventricular conduction: using electronic medical records as a tool for genome science. Circulation (2010) 3.35

Return of individual research results from genome-wide association studies: experience of the Electronic Medical Records and Genomics (eMERGE) Network. Genet Med (2012) 3.29

Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21

Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet (2013) 3.21

Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum (2005) 3.17

ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med (2011) 3.12

ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace (2006) 3.11

Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors. J Rheumatol (2006) 3.10

De novo rates and selection of large copy number variation. Genome Res (2010) 3.08

Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther (2006) 3.06

Preserving the genetic integrity of human embryonic stem cells. Nat Biotechnol (2005) 3.03

Renin-angiotensin system gene polymorphisms and atrial fibrillation. Circulation (2004) 3.02

The Next PAGE in understanding complex traits: design for the analysis of Population Architecture Using Genetics and Epidemiology (PAGE) Study. Am J Epidemiol (2011) 2.98

Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation (2002) 2.98

Sudden cardiac death prediction and prevention: report from a National Heart, Lung, and Blood Institute and Heart Rhythm Society Workshop. Circulation (2010) 2.94

Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood (2010) 2.93

Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Ann Intern Med (2010) 2.90

Estimating coverage and power for genetic association studies using near-complete variation data. Nat Genet (2008) 2.80

KCNH2-K897T is a genetic modifier of latent congenital long-QT syndrome. Circulation (2005) 2.78

Metabolic syndrome and risk of development of atrial fibrillation: the Niigata preventive medicine study. Circulation (2008) 2.72

Using synthetic templates to design an unbiased multiplex PCR assay. Nat Commun (2013) 2.72

Common sodium channel promoter haplotype in asian subjects underlies variability in cardiac conduction. Circulation (2006) 2.72

Identification, replication, and functional fine-mapping of expression quantitative trait loci in primary human liver tissue. PLoS Genet (2011) 2.68